Axxcess Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Axxcess Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$115K	Buy	37,516 +5,338	+17%	+$20.6K	﹤0.01%	371
2025 Q4	$132K	Buy	32,178 +1,378	+4%	+$6.83K	﹤0.01%	1016
2025 Q3	$150K	Sell	30,800 -10,025	-25%	-$52.6K	﹤0.01%	906
2025 Q2	$207K	Buy	40,825 +510	+1%	+$2.5K	﹤0.01%	837
2025 Q1	$213K	Sell	40,315 -825	-2%	-$6.01K	0.01%	794
2024 Q4	$278K	Sell	41,140 -2,744	-6%	-$18.4K	0.01%	691
2024 Q3	$289K	Buy	43,884 +1,795	+4%	+$12.9K	0.01%	698
2024 Q2	$316K	Buy	42,089 +4,704	+13%	+$41K	0.01%	634
2024 Q1	$373K	Buy	37,385 +14,388	+63%	+$160K	0.01%	610
2023 Q4	$227K	Buy	+22,997	New	+$164K	0.01%	739

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Axxcess Wealth Management's RXRX Position: Q1 2026 in Review

Axxcess Wealth Management increased its Recursion Pharmaceuticals (RXRX) stake by 17% in Q1 2026, buying an estimated $20.6K and bringing the position to 37,516 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #371.

Axxcess Wealth Management first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $373K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Axxcess Wealth Management held 37,516 shares of Recursion Pharmaceuticals worth $115K as of Q1 2026.
Axxcess Wealth Management bought 5,338 Recursion Pharmaceuticals shares in Q1 2026, an estimated $20.6K.
Recursion Pharmaceuticals made up ﹤0.01% of Axxcess Wealth Management's portfolio in Q1 2026, its #371 holding.
Axxcess Wealth Management first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Axxcess Wealth Management's Recursion Pharmaceuticals position peaked at $373K in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Axxcess Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.